Insider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Purchases 200,000 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra purchased 200,000 shares of the company’s stock in a transaction that occurred on Friday, March 21st. The shares were purchased at an average cost of $0.58 per share, with a total value of $116,000.00. Following the completion of the acquisition, the director now owns 200,000 shares in the company, valued at $116,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Lyell Immunopharma Stock Down 6.1 %

Shares of LYEL traded down $0.03 during mid-day trading on Tuesday, hitting $0.53. 440,470 shares of the company’s stock were exchanged, compared to its average volume of 1,045,818. The firm has a market cap of $155.05 million, a price-to-earnings ratio of -0.66 and a beta of -0.41. The stock’s 50-day simple moving average is $0.61 and its 200-day simple moving average is $0.87. Lyell Immunopharma, Inc. has a 52 week low of $0.48 and a 52 week high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Several hedge funds and other institutional investors have recently made changes to their positions in LYEL. Centiva Capital LP acquired a new stake in shares of Lyell Immunopharma in the 3rd quarter valued at $31,000. Graham Capital Management L.P. bought a new stake in Lyell Immunopharma during the 4th quarter worth $33,000. RPO LLC acquired a new position in Lyell Immunopharma in the 4th quarter worth about $42,000. Intech Investment Management LLC bought a new position in Lyell Immunopharma in the third quarter valued at about $52,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Lyell Immunopharma during the third quarter valued at about $52,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.